Eli Lilly’s investigational oral GLP-1 receptor agonist orforglipron demonstrated significant weight reduction and blood sugar improvements in adults with obesity or overweight and type 2 diabetes. The Phase III Attain-2 trial showed an average weight loss up to 11% at the highest dose over 72 weeks, with meaningful A1C reductions and cardiometabolic risk factor improvements. Despite trailing competitors like Novo Nordisk in FDA submission timing, Lilly plans to file soon, aiming to provide an oral alternative to injectable GLP-1 therapies.